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Abstract
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by the expansion of a CAG
trinucleotide repeat in the HTT gene encoding huntingtin. The disease has an insidious course, typically progressing
over 10-15 years until death. Currently there is no effective disease-modifying therapy. To better understand the HD
pathogenic process we have developed genetic HTT CAG knock-in mouse models that accurately recapitulate the
HD  mutation  in  man.  Here,  we  describe  results  of  a  broad,  standardized  phenotypic  screen  in  10-46  week  old
heterozygous HdhQ111 knock-in mice, probing a wide range of physiological systems. The results of this screen
revealed a number of behavioral abnormalities in  HdhQ111/+ mice that include hypoactivity, decreased anxiety,
motor learning and coordination deficits, and impaired olfactory discrimination. The screen also provided evidence
supporting subtle cardiovascular, lung, and plasma metabolite alterations. Importantly, our results reveal that a single
mutant HTT allele in the mouse is sufficient to elicit multiple phenotypic abnormalities, consistent with a dominant
disease process in patients. These data provide a starting point for further investigation of several organ systems in
HD, for the dissection of underlying pathogenic mechanisms and for the identification of reliable phenotypic endpoints
for therapeutic testing.
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Huntington’s  disease  (HD)  is  a  dominantly  inherited
neurodegenerative  disorder  characterized  by  abnormal
voluntary  and  involuntary  movements,  cognitive  impairment
and psychiatric disturbances. Onset typically occurs in mid-life,
relentlessly leading to death after ~10-15 years [1]. While the
brain  is  the  primary  site  of  pathology,  with  neurons  in  the
striatum and cortex being particularly vulnerable, multiple non-
neuronal abnormalities including weight loss and cardiac failure
occur in the disease [2].
HD is caused by an expansion >35 repeats of a polymorphic
CAG repeat tract within exon 1 of the HTT gene, elongating a
glutamine stretch at the amino-terminus of an ~350 kDa protein
called huntingtin [3]. Stringent genotype-phenotype analyses in
HD patients reveal that the length of the expanded CAG repeat
is the predominant factor determining the rate of the process
that leads to onset of motor symptoms. Further, onset age is
not  influenced  by  either  the  normal  CAG  allele  or  by  the
presence of a second mutant allele, indicating that the longer
expanded  CAG  allele  determines  motor  onset  in  a  fully
dominant  manner  [4].  These  data  are  consistent  with  the
polyglutamine expansion conferring a novel property/properties
on huntingtin, and/or enhancing a normal huntingtin function(s)
such  that  the  mechanism  determining  disease  onset  is
saturated by a single dose of the mutant protein [5,6].
A number of genetic rodent models have been developed to
investigate the pathogenesis of HD (see review by Heng et al.
[7]).  We  have  developed  lines  of  HTT  CAG  knock-in  mice
(HdhQ20,  HdhQ50,  HdhQ92,  HdhQ111)  on  various  genetic
backgrounds,  in  which  different  CAG  repeat  lengths  are
inserted  into  the  mouse  HTT  homologue  (Htt  or  Hdh)  gene
[8–10], accurately recapitulating human HTT alleles. Our long-
term goal is to identify in knock-in mice CAG length-dependent
phenotypes that are most proximal to the HTT CAG expansion
mutation and that are caused by a single mutant HTT allele as
in the majority of HD patients, as these are the most likely to
provide relevant targets for therapeutic intervention.
To date, several phenotypes have been identified in these
mice, mostly in the HdhQ92 and HdhQ111 lines harboring the
longest  repeat  tracts.  These  include  nuclear  huntingtin
localization  and  inclusion  phenotypes  [10-12],  somatic
instability  [9,10],  elevated  endoplasmic  reticulum  (ER)  stress
[13,14],  altered  cell  signaling  [15-17],  impaired  synaptic
plasticity  [18],  behavioral  abnormalities  [12,19-25]  and  late
stage brain pathology [12,26]. A number of these phenotypes
were observed in heterozygous mice, varied with CAG length
and  displayed  striatal  selectivity,  consistent  with  a  dominant
CAG  length-dependent  mechanism  that  determines  disease
onset in patients [11,14].
The  complexity  of  the  disease  and  its  multisystemic
manifestations  highlight  the  need  for  better,  more  global,
unbiased and standardized phenotyping. Here, as part of our
ongoing  phenotyping  effort,  we  report  results  from  a  broad,
standardized  phenotypic  screen  in  heterozygous  HdhQ111
mice on a C57BL/6J genetic background, in collaboration with
the  German  Mouse  Clinic  (GMC)  (www.mouseclinic.de).  We
have  thus  identified  a  number  of  novel  phenotypes  in  mice
ranging from 10 to ~50 weeks of age that highlight neurological
deficits  but  also  indicate  deficiencies  in  a  number  of  other
organ  systems.  The  results  of  these  analyses  provide  an
important  starting  point  for  further  exploration  of  underlying
disease  mechanisms  and  potential  endpoints  for  testing  of
genetic or pharmacological modifiers.
Materials and Methods
Mice
Mouse work was in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals. This
study  was  reviewed  and  approved  by  the  Massachusetts
General  Hospital  (MGH)  Subcommittee  of  Research  Animal
Care  (SRAC),  which  serves  as  the  Institutional  Animal  Care
and  Use  Committee  (IACUC)  for  MGH.  The  study  was  also
reviewed and approved to be in accordance with German legal
guidelines and by authority of the Regierung von Oberbayern.
Mice  used  in  this  study  were  the  HdhQ111  line  [9]  on  a
C57BL/6J  genetic  background  [27].  Mouse  genotyping  and
CAG repeat length determination were performed as described
previously  [28].  The  mice  used  in  the  screen  were
heterozygous  HdhQ111/+  mice  and  their  wild-type  Hdh+/+
littermates  generated  in  crosses  between  male  HdhQ111/+
C57BL/6J and female wild-type C57BL/6J mice (Jackson labs).
All mice used in the screen were born within one week of each
other and were separated based on sex but not genotype. At
5-6 weeks of age mice were shipped to the GMC and allowed
to acclimatize to their new environment for four weeks before
testing began at 11 weeks of age. Three pipelines of mice were
sent  to  the  GMC  for  phenotyping.  Pipeline  1  comprised  20
HdhQ111/+  (10  males,  CAG  117-129;  10  females,  CAG
117-126) and 20 Hdh+/+ (10 males,10 females) mice. Pipeline
2  comprised  20  HdhQ111/+  (10  males,  CAG  113-129;  10
females, CAG 117-126) and 21 Hdh+/+ (11 males, 10 females)
mice and pipeline 3 comprised 20 HdhQ111/+ (10 males, CAG
113-129; 10 females, CAG 117-126) and 20 Hdh+/+ (10 males,
10 females) mice. Follow-up studies were performed at MGH
using additional cohorts of HdhQ111 C57BL/6J mice. Cohort 1:
19  HdhQ111/+  (10  males,  CAG  124-128;  9  females,  CAG
124-129) and 20 Hdh+/+ (10 males, 10 females); cohort 2: 20
HdhQ111/+  (10  males,  CAG  121-128;  10  females,  CAG
120-128) and 20 Hdh+/+ (10 males, 10 females); cohort 3: 19
HdhQ111/+ (10 males, CAG 124-132; 9 females, CAG 123-129
CAGs) and 18 Hdh+/+ (9 males, 9 females).
Phenotyping
The  GMC  screen  (www.mouseclinic.de)  comprises
extensive,  standardized  phenotyping  in  the  realms  of
dysmorphology,  cardiovascular  health,  energy  metabolism,
clinical  chemistry,  eye,  lung  function,  molecular  phenotyping,
behavior,  neurology,  nociception,  immunology,  steroid
metabolism and pathology. The phenotypic tests that were part
of  the  GMC  screen  are  summarized  in  Table  S1,  and
behavioral tests perfomed in MGH cohorts are summarized in
Table S2. Note that not all animals in each GMC pipeline were
tested in each paradigm; the specific numbers that relate to the
data are indicated in the figure legends. Phenotyping screens
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methods described in [29–31]. Detailed methods for the results
described in this manuscript are also provided in a Methods S1
file.
Statistical analyses
Data  were  generally  analyzed  either  by  2-way  ANOVA
(genotype, sex and genotype x sex interaction as variables) or
independently  in  males  and  females  using  2-tailed  unpaired
Student’s  t-tests.  Depending  on  the  nature  of  the  test,  GMC
typically analyzes their screen data using one or other of these
statistical tests. Rotarod learning data that incorporated time as
a variable was also analyzed using linear mixed models that
included day of testing and a day x genotype interaction term.
Where  we  have  observed  a  significant  genotype  effect  in
ANOVA  we  have  performed  Sidak  correction  for  multiple
comparisons  (mutant  versus  wild-type  for  males  and  mutant
versus wild-type for females). We report nominal p values in
the  text,  unless  specifically  stated  otherwise.  Graphs  are
annotated with asterisks to indicate the sex-stratified p values
using  t-tests,  or  the  sex-stratified  p  values  following  Sidak’s
multiple testing correction. Results throughout are displayed as
mean±standard error (SEM). A p-value <0.05 was used as the
level of signiﬁcance. This study is designed to be a hypothesis-
generating  screen.  We  have  therefore  reported  both  results
with nominally significant p values, as well as those that do not
reach statistical significance but which may be of interest in the
context of other data presented here or elsewhere.
Results
Table  1  summarizes  the  phenotypes  that  are  described
below in HdhQ111/+ mice.
General phenotypic observations
A  whole  body  visual  assessment  of  HdhQ111/+  mice  and
their  wild-type  littermates,  carried  out  at  10  weeks  of  age,
revealed  no  abnormalities  in  body  appearance,  craniofacial/
head morphology, limbs, digits, tail, eye, ears, teeth, vibrissae,
coat,  hair  follicles,  skin  pigmentation/condition,  muscle
morphology,  seizures,  motor  capabilities/coordination,
movement,  eating/drinking  behavior,  respiratory  system,  or
reproductive/urinary  system.  Dual  energy  X-ray  absorption
(DEXA)  analyses  at  16  weeks  of  age  also  revealed  the
absence  of  any  bone  morphological  abnormalities  with  the
exception  of  a  slight  increase  in  bone  mineral  density  in
females and decrease in males (females: Hdh+/+ (N=10) 46±1
mg/cm2,  HdhQ111/+  (N=10)  49±1  mg/cm2;  males:  Hdh+/+
(N=10)  49±1  mg/cm2,  HdhQ111/+  (N=10)  46±1  mg/cm2;
ANOVA  sex  x  genotype  interaction  p<0.05).  No  hearing  (10
weeks)  or  eye  abnormalities  (15,  17  weeks)  were  detected.
Macroscopic assessment and a broad histological examination
by hematoxylin and eosin staining at 19 weeks of age did not
reveal  overt  pathology  in  any  tissue.  Together  these
observations support previous findings that huntingtin’s critical
role  in  development  is  not  compromised  by  the  CAG  repeat
expansion [8], and are consistent with a single expanded CAG
allele  eliciting  subtle  gain  of  function  phenotypes  and  an
insidious disease course.
Analyses of neurological dysfunction
To  probe  neurological  dysfunction  HdhQ111/+  mice
underwent a series of behavioral and neurological tests (Table
S1). HdhQ111/+ mice did not show any abnormalities in grip
strength or in the modified SHIRPA test at 11 weeks (data not
shown). Analyses of acoustic startle and pre-pulse inhibition at
13  weeks  indicated  very  minor,  though  not  statistically
significant,  reductions  in  acoustic  startle  response  but  no
alterations  in  pre-pulse  inhibition  (Figure  S1).  Behavioral
phenotypes identified are described in subsequent sections.
Table 1. Summary of HdhQ111/+ phenotypes.
Age (wk)   Test Phenotype
11 Open field (light)
Increased time in center; increased time
resting in center
  Dark/light box (Increased number of entries)
12 Rotarod Increased motor learning
 
Cardiovascular
parameters
Increased heart rate
14-16 Social discrimination Impaired in males
16 DEXA
aBone mineral density increased in females,
decreased in males; (decreased fat content)
16-19 Clinical chemistry
Decreased glucose in free-fed mice;
(decreased cholesterol in free-fed mice)
18 Lung function Increased tidal volume
19
Cardiovascular
parameters
aIncreased heart weight/tibia length in
females, decreased in males
24 Rotarod Decreased motor learning
b28-36 Olfaction Impaired olfactory discrimination
c40 Open field (dark)
Increased time in center; decreased distance
covered; decreased velocity; decreased
ambulatory time; ddecreased stereotypy;
ddecreased vertical time
46 Catwalk
Decreased stride length; decreased cruciate
step pattern
  Vertical pole descent Increased time to turn and descend
  Weight Decreased in females; (decreased in males)
Standard  font  indicates  nominally  significant  p-values  (p<0.05);  italic  font  with
parentheses indicates a trend with p-values >0.05. See text for details.
a Significant genotype x sex interaction;
b Olfactory discrimination deficit also observed in male mice at 24-27 weeks and
42-47 weeks and in female mice at 50-56 weeks.
c Open field testing in the dark in a separate cohort at 56-59 weeks showed same
phenotypes as cohort at 40 weeks with the exception that the 56-59 week mice did
not  spend  more  time  in  the  center  of  the  field  or  show  a  difference  in  vertical
activity.
d Noted in periphery of open field only.
doi: 10.1371/journal.pone.0080923.t001
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responses to a novel environment
Behavioral response to a novel environment was tested in
the open field arena in the light phase of the diurnal cycle at 11
weeks of age. HdhQ111/+ mice did not show any difference in
distance traveled, speed of travel or rearing activity (data not
shown),  revealing  the  lack  of  significant  alteration  of
exploratory  or  locomotor  activity  in  this  paradigm.  However,
HdhQ111/+ mice were found to spend more time in the center
of  the  open  field  than  their  wild-type  littermates  (ANOVA
genotype effect p<0.05) (Figure 1A) and tended to rest in the
center  for  longer  periods  (ANOVA  genotype  effect  p<0.05)
(Figure 1B). As mice tend to be averse to open spaces, these
findings suggested that HdhQ111/+ mice exhibited decreased
anxiety-like  behavior.  Repeated  measures  analyses  did  not
reveal  any  significant  differences  in  habituation  to  the  novel
environment over time for any measure (data not shown).
As this was a very early time-point relative to the onset age
for  other  reported  behavioral  phenotypes  in  these  mice  we
were interested to test the reproducibility of this finding across
different laboratories/environments by testing cohorts of mice in
a similar open field paradigm in follow-up studies at MGH. Note
that  the  open  field  apparatus  differed  between  the  two
institutions (Materials and Methods). We were able to confirm
the open field phenotypes of increased time in the center in
one cohort (MGH cohort 1, mean age 9.6 weeks: males Hdh
+/+  280±20s  vs.  HdhQ111/+  303±17s;  females  Hdh+/+
253±12s  vs  HdhQ111/+  339±25s;  ANOVA  genotype  effect
p<0.01),  in  female  mice  of  a  second  cohort  (MGH  cohort  3,
mean age 10.8 weeks: males Hdh+/+ 278±14s vs. HdhQ111/+
199±13s;  females  Hdh+/+  226±20s  vs  HdhQ111/+  301±16s;
ANOVA genotype-sex interaction effect p<0.0005) but not in a
third cohort (MGH cohort 2, mean age 9.25 weeks: males Hdh
+/+  277±19s  vs.  HdhQ111/+  273±25s;  females  Hdh+/+
292±16s  vs  HdhQ111/+  285±17s;  ANOVA  genotype  effect
p=0.80). Taken together our results suggest that HdhQ111/+
mice  do  indeed  display  open  field  phenotypes  as  early  as
approximately  10  weeks  of  age  that  are  robust  enough  to
withstand  differences  between  mouse  testing  facilities/
apparatus. However, these phenotypes are not fully penetrant
at this age, and appear more pronounced in females than in
males.
An  additional  test  of  anxiety  using  a  dark-light  box  at  11
weeks of age was performed on a separate cohort of mice at
the  GMC  (pipeline  3,  see  Table  S1).  In  the  dark-light  box,
HdhQ111/+ mice showed a trend towards an increased number
of  light  box  entries  (males:  Hdh+/+  13.8±1.0,  HdhQ111/+
15.7±1.4; females: Hdh+/+ 1.57±0.97, HdhQ111/+ 18.8±1.62;
ANOVA  genotype  effect  p=0.08),  indicating  reduced  anxiety
compared to wild-type mice and consistent with findings in the
Figure 1.  HdhQ111/+ mice display reduced anxiety-like behavior in the open field.  HdhQ111/+ and wild-type littermates were
tested in the open field arena at 11 weeks of age during the light phase of the diurnal cycle. HdhQ111/+ mice were found to spend
more time in the center of the open field arena (A), and when in the center, spent more time resting (B). Y-axis in (A) shows the
percentage of time over the 20-minute testing period spent in the center, and in (B) the total time resting in the center in the 20-
minute testing period. N=20 HdhQ111/+ mice (10 males, 10 females) and N=21 Hdh+/+ mice (11 males, 10 females). Bars show
mean±SEM. ANOVA genotype effect p<0.05 for both (A) and (B).
doi: 10.1371/journal.pone.0080923.g001
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HdhQ111/+  mice  display  behavior  consistent  with  decreased
anxiety.
HdhQ111/+ mice are hypoactive in the dark phase
Given the above findings we were interested to use the open
field arena to examine mouse activity during the dark (active)
phase. We performed open field testing on a cohort of mice at
MGH (MGH cohort 1) at 40 weeks of age in the dark phase.
The results of this test are displayed in Figure 2. HdhQ111/+
mice spent more time in the center of the open field (Figure 2A:
ANOVA genotype effect p<0.02), covered less distance in the
open field arena (Figure 2B: ANOVA genotype effect p<0.005),
moved at a decreased velocity (Figure 2C: ANOVA genotype
effect  p<0.001)  and  spent  less  ambulatory  time  (Figure  2D:
ANOVA  genotype  effect  p<0.005)  than  their  wild-type
littermates. All of these effects were seen in both the center
and periphery of the open field (data not shown separately for
center  and  periphery).  Significantly  reduced  stereotypy  time
(Figure 2E: ANOVA genotype effect p<0.001) and vertical time
Figure 2F: ANOVA genotype effect p<0.05) were also noted in
the periphery of the open field. These results suggest that by
40 weeks of age HdhQ111/+ mice are hypoactive and display a
measure  of  decreased  anxiety  that  was  already  observed  at
10-11 weeks of age. Open field analysis in the dark phase was
also carried out in an independent cohort of mice (MGH cohort
3) at 56-59 weeks of age (Table S3). The 56-59 week cohort
displayed  many  of  the  same  phenotypes  as  the  40  week
cohort,  notably  reduced  distance  travelled,  reduced  velocity,
reduced ambulatory time and reduced stereotypy time in the
periphery.  Time  in  the  center  of  the  open  field  was  not
significantly different, though we note that the 56-59 week old
mice overall spent less time in the center than the 40 week
mice (Figure 2, Table S3). Overall, there was a high degree of
reproducibility between the 40- and 56-59- week cohorts, with
hypoactivity being a notable common feature.
Further longitudinal open field testing under both light and
dark paradigms will be needed to better assess the timeframe
within  which  these  behavioral  phenotypes  become  manifest
and their potentially progressive nature.
HdhQ111/+ mice exhibit motor learning and
coordination deficits
Tests of motor function in the GMC screen comprised the
accelerating  rotarod,  gait  analysis  and  vertical  pole  descent.
Rotarod  analysis  was  carried  out  at  12  weeks  of  age.  As
assessed in a single day trial, HdhQ111/+ mice did not show
any altered latency to fall off the rotarod. However, in a three-
day trial paradigm to assess motor learning, HdhQ111/+ mice
showed increased latencies compared to Hdh+/+ mice (linear
mixed  effects  model,  genotype  effect  p<0.05)  (Figure  3A,C).
Learning over test days was somewhat increased in mutants
(Figure  3A,C,E)  but  missed  statistical  significance  when
analyzed by including a genotype x day interaction term in the
model (linear mixed effects model, genotype x day p=0.097).
To explore this phenotype further, a cohort of mice was tested
in the same rotarod paradigm at MGH at 10 weeks of age and
again at 24 weeks of age. At 10 weeks of age HdhQ111/+ did
not show significant genotype differences in latency to fall or
learning, consistent with the slightly younger age of the MGH
cohort compared to the GMC cohort (data not shown). At 24
weeks of age we did not find that mutant and wild-type mice
differed  significantly  in  latency  to  fall  (linear  mixed  effects
model, genotype effect p=0.83) (Figure 3B, D). However, we
found that many mice, both mutant and wild-type, showed a
worsened, rather than an improved performance, over the 3-
day  trial  (Figure  3B,  D,  F).  Interestingly  however,  this  effect
was  more  pronounced  in  HdhQ111/+  mice  than  in  wild-type
controls (linear mixed effects model, genotype x day p=0.024).
Performing  a  2-way  ANOVA  using  “improvement”  as  the
dependent variable followed by a Sidak multiple correction test
indicated that the worsened performance on the rotarod of 24
week HdhQ111/+ mice was largely driven by an effect in the
males (Figure 3F) (ANOVA genotype effect p<0.05; corrected p
value in males =0.029). It appears that under this experimental
paradigm the 24-week old mice may not have had sufficient
time  to  train  on  the  rotarod  in  order  to  improve  their
performance.  However,  these  conditions  appear  to  have
inadvertently exposed a motor learning deficit in mutant mice.
Note that improvement (or worsening) in performance over 3
days was not influenced by mouse weight (data not shown).
Gait analysis in 46-week old mice revealed that HdhQ111/+
mice exhibited a reduced stride length, mainly seen in males
(ANOVA genotype effect p<0.05) (Figure 4A,B), and consistent
with a reduced stride length observed in CD1.HdhQ111 mice
[12].  In  addition,  analyses  of  the  step  pattern  sequence
revealed  that  HdhQ111/+  mice  used  the  more  advanced
cruciate step pattern less than the wild-type controls (ANOVA
genotype effect p<0.05) (Figure 4C,D). The same mice were
also tested at 46 weeks of age for their ability to descend a
vertical pole. HdhQ111/+ mice needed more time than the wild
type controls to turn around and to descend (ANOVA genotype
effect p<0.05) (Figure 4, E.F).
Together,  these  data  indicate  a  biphasic  response  in
HdhQ111/+ mice, with evidence of improved motor learning at
an early age, followed by impaired motor learning and motor
performance as the mice age.
HdhQ111/+ mice show impaired social discrimination
Recognition memory, the ability to discriminate familiar and
unfamiliar stimuli, is impaired in HD [32]. To probe recognition
memory  in  HdhQ111/+  mice  we  employed  a  social
discrimination task that takes advantage of the innate drive to
investigate an unfamiliar compared to a familiar mouse. After
initial  exposure  to  a  test  mouse  the  experimental  subject
acquires  the  olfactory  signature  of  that  mouse.  Following  a
defined interval of time the experimental subject is reintroduced
to  the  test  mouse  together  with  an  unfamiliar  mouse.  The
significantly  longer  time  spent  investigating  the  unfamiliar
mouse  reflects  recognition  of  the  original  test  mouse.  Mice
were tested at 14-16 weeks of age in this paradigm for their
ability  to  discriminate  between  a  familiar  and  an  unfamiliar
mouse.  While  wild-type  males  spent  significantly  more  time
investigating an unfamiliar mouse than a familiar mouse, male
HdhQ111/+  mice  failed  to  display  this  discriminatory  ability
(Figure 5A). In contrast female HdhQ111 mice did not exhibit
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their  wild-type  littermates  (Figure  5B).  The  failure  to
discriminate between familiar and unfamiliar mice suggests that
male HdhQ111/+ mice may have impaired recognition memory.
HdhQ111/+ mice are impaired in their ability to
discriminate odors
Premanifest  HD  mutation  carriers  exhibit  olfactory  deficits
[33-38]. However, olfaction has not previously been reported at
the functional level in a mouse model of HD. Given the early
detection of this deficit in HD mutation carriers, and the highly
developed sense of smell in the mouse, we took advantage of
olfactory  tests  that  had  been  developed  by  the  GMC  in  our
HdhQ111/+ screen [39]. These tests were performed between
28 and 36 weeks of age. Mice were trained to recognize one of
two odors (strawberry or apple) and then tested both for their
sensitivity  to  recognize  the  odor  on  which  they  had  been
trained following serial binary dilutions, and for their ability to
discriminate  the  odor  on  which  they  had  been  trained  when
mixed  with  the  alternative  odor.  Mutant  mice  showed  no
difference in olfactory sensitivity (Figure 6A,B). However, both
male and female mutant mice displayed a clear deficit in their
ability to discriminate between binary mixtures of the two odors
(Figure  6C,D).  Compared  to  male  Hdh+/+  mice,  male
HdhQ111/+  mice  showed  an  impairment  in  their  ability  to
choose the correct odor when it comprised 53% (t-test p=0.04)
or 51% (t-test p=0.01) of the mixture. Female HdhQ111/+ mice
appeared more severely impaired in this task; they showed a
significant difference compared to female Hdh+/+ mice in odor
discrimination at mixtures of 55% (t-test p=0.0001) and 51% (t-
test p=0.04). Further, even at 100% of the trained odor (ie. no
mixture),  female  mutants  showed  a  difference  compared  to
Figure 2.  HdhQ111/+ mice exhibit hypoactivity in the open field.  HdhQ111/+ and wild-type littermates were tested in the open
field arena at 40 weeks of age during the dark phase of the diurnal cycle. Consistent with observations in younger mice, HdhQ111/+
mice spent more time in the center of the open field (A). HdhQ111/+ mice also exhibited a decrease in distance traveled (B), velocity
(C) and in time spent in ambulatory motion (D) in the whole testing arena, indicating that they were hypoactive. (E) and (F) show
time spent in stereotypic movements or rearing, respectively, in the periphery of the open field. All measurements are over the 20-
minute testing period. N=19 HdhQ111/+ mice (10 males, 9 females) and 20 Hdh+/+ mice (10 males, 10 females). Bars show mean
±SEM. All tests showed a significant genotype p value in a 2-way ANOVA (see text for p values). Asterisks indicate adjusted p
values following multiple testing correction. * p<0.05; **p<0.01; ***p<0.001.
doi: 10.1371/journal.pone.0080923.g002
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p=0.0002).
The  olfactory  discrimination  test  was  repeated  at  MGH  in
male mice of 24-27 weeks of age (MGH pipeline 1) and in a
separate group of male and female mice (MGH pipeline 3) at
older  ages  (males  42-47  weeks;  females  50-56  weeks).  At
24-27  weeks  of  age,  male  HdhQ111/+  mice  showed  an
impairment  in  their  ability  to  discriminate  between  the  two
odors  in  the  70%  (t-test  p=0.007)  and  53%  (t-test  p=0.03)
mixtures  (Figure  S2).  As  we  had  observed  genotype
differences in odor recognition prior to the mixing steps (see
“100%” on graphs in Figure 6D and Figure S2) we explored
further  a  potential  training  deficit  in  HdhQ111/+  mice  in  our
testing of the older MGH cohort by evaluating the number of
correct/incorrect  choices  during  training  (see  Materials  and
Methods for details of training steps) in addition to documenting
the  number  of  correct/incorrect  choices  upon  mixing  of  the
odors  (Figure  6E,F).  Male  HdhQ111/+  mice  exhibited  a
discrimination deficit at the 70% dilution step (t-test p=0.001)
(Figure 6E), while female HdhQ111/+ mice exhibited a training
deficit,  apparent  at  training  step  2  (t-test  p=0.0095)  and  the
100%  odor  step  (t-test  p=0.0006)  but  did  not  show  any
significant difference in subsequent odor discrimination (Figure
6F).  The  more  pronounced  training  deficit  in  females  is
consistent with the original GMC findings (compare “100%” in
graphs of Figure 6C and D). Notably, we did not observe any
genotype differences in training step 1, in which the mice are
trained to look for the chocolate reward, but only in subsequent
steps in which mice are trained to associate the conditioned
odor with the reward. This argues against a perceptual deficit in
the  mutant  mice  but  indicates  a  possible  olfactory  learning
deficit.  It  is  not  surprising  that  there  are  differences  in  the
Figure 3.  Performance on the accelerating rotarod.  HdhQ111/+ and wild-type littermates were tested at 12 weeks (A, C, E) and
24 weeks (B, D, F) on an accelerating rotarod over three consecutive days and latency to fall (seconds, s) was recorded on each
day (A-D). Improvement (E, F) was measured as the difference in latency to fall on day 3 compared to day 1, with positive values
indicating improvement and negative values indicating a worsening performance. 12 weeks: N=20 HdhQ111/+ mice (10 males, 10
females and 21 Hdh+/+ mice (11 males, 10 females); 24 weeks: N= 20 HdhQ111/+ mice (10 males, 10 females) and 20 Hdh+/+
mice (10 males, 10 females). Bars show mean±SEM. * Adjusted p value (p<0.05) following multiple testing correction.
doi: 10.1371/journal.pone.0080923.g003
Huntington's Disease Mouse Model Phenotype Screen
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e80923precise mixtures at which a deficit is seen in mutants in the
GMC  and  MGH  studies  as  there  are  many  factors  that  are
extremely difficult to control, even in the same facility, which
could influence the results. Differences may also be due in part
to an age-related decline in the ability of the wild-type mice to
discriminate odors (compare wild-type mice at 28-36 weeks in
Figures  6C  and  D  that  maintain  %  correct  choice  across
dilutions with wild-type mice at 42-47 weeks in Figure 6E and
at 50-56 weeks in Figure 6F that show a decline in % correct
choice  across  dilutions).  These  caveats  notwithstanding,  our
data  indicate  the  presence  of  an  olfactory  impairment  in
HdhQ111/+  mice  that  may  at  least  in  part  result  from  an
olfactory learning deficit.
Olfactory  memory  was  also  tested  in  the  GMC  cohort  by
testing the ability of the mice to recognize the odor on which
they had been trained after an interval of 16-17 weeks or 20-22
Figure  4.    Motor  deficits  in  aged  HdhQ111/+  mice.    HdhQ111/+  and  Hdh+/+  mice  at  46  weeks  of  age  were  tested  on  an
automated CatWalk system (A-D) and for their ability to descend a vertical pole (E,F). HdhQ111/+ mice showed reduced Right by
Left hindlimb stride length (A,B), a decreased cruciate step pattern frequency of pattern left front-right front-left hind-right hind (C,D)
and an increased time to descend a vertical pole (total duration being the time taken to turn at the top of the pole and descend to the
bottom). . For the CatWalk N=10 per sex and genotype; for the pole descent, males N=8 Hdh+/+, N=9 HdhQ111/+, females N=10
per genotype. Plotted are Tukey box-whisker graphs. All tests showed a significant genotype p value in a 2-way ANOVA. * Adjusted
p value (p<0.05) following multiple testing correction.
doi: 10.1371/journal.pone.0080923.g004
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test  (Figure  S3).  While  wild-type  mice  were  still  able  to
recognize  the  correct  odor  after  20-22  weeks,  female
HdhQ111/+ mice displayed a marked inability to do so after this
time  interval  (20  week  females:  chi  squared  test  p=0.0016).
These  findings  support  an  olfactory  learning  and  memory
deficit  that  is  more  pronounced  in  female  than  male
heterozygous mutant mice.
Metabolic assessment of HdhQ111/+ mice
With  increasing  indications  that  HD  can  be  considered  a
multisystemic  disease  we  were  interested  in  peripheral
phenotypes in HdhQ111 mice. There is considerable evidence
for an energy deficit in HD. Patients exhibit progressive weight
loss  that  appears  to  stem  from  an  increased  metabolic  rate
[40,41]. Body weight was measured in three cohorts of mice at
five  time  points  from  11-46  weeks  of  age.  No  genotype
differences in body weight were found in mice up to 19 weeks
of  age  (Table  S4)  although  interestingly,  there  was  a  trend
towards a lower fat content in HdhQ111/+ mice at 16 weeks of
age (males Hdh+/+ 10.68±2.00% vs. HdhQ111/+ 8.82±1.47%;
females Hdh+/+ 6.57±1.95% vs. HdhQ111/+ 4.51±1.53%). By
46  weeks  of  age  mutant  mice  exhibited  a  slight  weight
decrease compared to their wild-type littermates (Table S4: t-
test:  males  p=0.09;  females  p<0.05).  Consistent  with  the
comparable weights between mutant and wild-type mice up to
19 weeks of age indirect calorimetry did not identify alterations
in measures relating to energy uptake and expenditure (mean
O2  consumption  rate,  respiratory  exchange  ratio,  heat
production,  food  consumption,  rectal  body  temperature  or
activity) at 13 weeks of age (data not shown). HD patients have
also  been  found  to  exhibit  altered  glucose  homeostasis,
including  a  higher  incidence  of  diabetes  in  some  studies
[42-44].  We  did  not  find  evidence  of  glucose  intolerance  in
HdhQ111/+ mice as determined by an intraperitoneal glucose
tolerance test (IpGTT) at 14 weeks (Figure S4). We noted that
in the IpGTT blood peak glucose levels, particularly in female
HdhQ111/+  mice,  were  consistently  very  slightly  lower  than
those  of  wild-type  mice,  although  this  difference  was  not
statistically  significant.  (Figure  S4).  Consistent  with  this,  an
independent cohort of female HdhQ111/+ mice at 16-19 weeks
of age showed significantly (p<0.05) lower blood glucose levels
in  a  fed  state  (Figure  7,  Table  S5),  though  fasting  glucose
levels  were  not  altered  (Table  S5).  Note  that  other  blood
metabolites,  proteins,  enzyme  activities  and  electrolytes,
measured at 16-19 weeks, were largely unaltered (Table S5).
Of interest, cholesterol levels showed a trend towards reduced
levels in free-fed HdhQ111/+ mice (Table S5) consistent with
altered cholesterol metabolism previously reported in patients
and mice [45]. Taken together, these results indicate that up to
approximately  19  weeks  of  age,  a  single  mutant  HTT  allele
does  not  grossly  disrupt  homeostasis  in  the  mice.  However,
subtle  alterations  in  young  HdhQ111/+  mice,  together  with
weight loss in older mice, are suggestive of ongoing metabolic
disturbances that warrant further investigation.
Figure 5.  Male HdhQ111/+ mice display a social recognition deficit.  In the sample phase, an ovariectomized (OVX) female
mouse was introduced into a cage with a male (A) or female (B) experimental HdhQ111/+ or Hdh+/+ mouse and time spent in
olfactory investigation was recorded for 4 minutes after which time the OVX female was removed. After two hours, in the test phase,
the experimental mouse was returned to the testing cage with both the familiar OVX mouse and a novel unfamiliar OVX female and
time spent in olfactory investigation with both the familiar and unfamiliar mouse recorded for 4 minutes. Males: N=10 per genotype;
females: N=10 per genotype. Bars show mean±SEM. * p<0.05; ** p<0.01 (2-tailed unpaired Student’s t-test comparing time spent
investigating familiar and unfamiliar mouse).
doi: 10.1371/journal.pone.0080923.g005
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mice suggest autonomic nervous system defects
Blood pressure parameters were determined at 12 weeks of
age  (GMC  pipeline  1;  see  Table  S1).  No  differences  were
found in systolic, diastolic or mean arterial pressure compared
between HdhQ111/+ and Hdh+/+ mice (Table S6). However,
HdhQ111/+ mice were found to have an increased heart rate
compared  to  Hdh+/+  mice  (ANOVA  genotype  effect  p<0.05;
Figure  8A,  Table  S6).  Additional  measures  of  heart  disease
(heart  weight,  proatrial  natriuretic  peptide  (Nt  proANP))  were
made in a separate cohort of mice (GMC pipeline 2; see Table
S1) at 19 weeks of age (Table S6). There were no genotype
differences in Nt proANP levels, however we identified a sex-
genotype  interaction  (ANOVA  interaction  effect  p<0.05)  for
heart  weight  normalized  to  tibia  length,  with  female  mutants
exhibiting  a  slightly  increased  heart  weight/tibia  length  and
male  mutants  exhibiting  a  slightly  lower  heart  weight/tibia
length compared to wild-type mice (Table S6). However, the
effect is small, and together with the lack of any change in Nt
proANP we conclude that there are no obvious signs of heart
disease in these mice. Cardiac function was also assessed in a
further  cohort  of  mice  at  69  weeks  of  age.  No  structural
abnormalities,  altered  cardiac  function  or  electrophysiological
properties were detected using a combination of ECG under
anesthesia,  ambulatory  ECG  and  in  vivo  electrophysiology
(Table S7). Note that in this older cohort, the genotype-specific
Figure 6.  HdhQ111/+ mice exhibit an olfactory discrimination deficit.  A,B: olfactory sensitivity was determined by testing the
ability of the mice to recognize binary dilutions of the scent on which they had been trained. Plotted on the y-axis is the number of
binary dilutions at which a particular mouse is able to recognize the scent. C-F: olfactory discrimination test. Mice were trained on a
scent [S+] (either strawberry or apple) and then tested for their ability to recognize decreasing proportions of this scent in a binary
mixture. C,D: test carried out at the GMC on mice at 28-36 weeks of age. N=10 per sex and genotype. E,F: test carried out at MGH
on males at 42-47 weeks of age and females 50-56 weeks of age. Males Hdh+/+ N=9, HdhQ111/+ N=10; females Hdh+/+ N=9,
HdhQ111/+ N=9). Pre: pre-training; T1: training step 1; T2: training step 2 (see Materials and Methods). Error bars show SEM. *
p<0.05; ** p≤0.01, ***p<0.005 in 2-tailed unpaired Student’s t-test comparing mutant and wild-type mice at each dilution.
doi: 10.1371/journal.pone.0080923.g006
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was a trend to a decreased heart rate in mutant mice (Table
S7). Taken together, these data indicate the lack of any major
cardiac defect in mice up to 69 weeks of age, but evidence for
an altered heart rate implicating an impact of the HTT mutation
on the autonomic nervous system (ANS).
Lung function was assessed at 18 weeks of age using whole
body  plethysmography  to  determine  spontaneous  breathing
patterns at activity and rest. During activity, male HdhQ111/+
mice exhibited an 8% increase in tidal volume (TV) compared
to  Hdh+/+  littermates  (t-test  male  mutant  versus  wild-type
p<0.05;  Figure  8B),  accompanied  by  secondary  increases  in
inspiratory flow rates and minute volumes (the product of the
TV and respiratory rate) (Table S8). Males also showed a trend
towards increased TV at rest, but this did not reach statistical
significance, likely because of the small number of mice that
actually showed resting behavior (Table S8). Higher TVs may
be  associated  with  increased  sympathetic  nervous  system
activation  [46],  consistent  with  the  increased  heart  rate  in
young  mice;  however  increased  tidal  volume  was  only
observed in males, and other signs of increased sympathetic
activity such as an elevated respiratory rate were not apparent
(Table  S8).  Together,  these  data  provide  evidence  of  mild
cardiovascular and lung abnormalities present by 18-19 weeks
of  age  and  suggest  a  potential  impact  of  the  HTT  CAG
mutation on the autonomic nervous system.
Discussion
Here we present results of a phenotyping screen carried out
in the accurate genetic HdhQ111 knock-in mouse model of HD
with  the  aim  of  uncovering  phenotypes  elicited  by  a  single
Figure 7.  Free fed glucose levels in HdhQ111/+ and Hdh+/+ mice.  Glucose levels were measured in free-fed mice at 16 weeks
of age (A) (N=10 for each sex and genotype) and again at 19 weeks (B) in the same cohort of mice (N=10 males for each genotype,
N=9 Hdh+/+ females and N=7 HdhQ111/+ females).
* p<0.05 (2-tailed unpaired Student’s t-test). Plotted are Tukey box-whisker graphs.
doi: 10.1371/journal.pone.0080923.g007
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of  HD  patients.  This  is  the  first  attempt  at  a  comprehensive
screen  of  an  HD  mouse  model  aimed  at  an  extensive
characterization  across  multiple  physiological  systems.  It  is
important  to  note  that  in  these  standardized  screens  each
phenotypic test is carried out at a specific age(s). Therefore,
the screen does not reveal information on the progression of
any particular mutant phenotype over time or on its potentially
transient  nature.  Conversely,  a  negative  result  does  not
necessarily  preclude  a  particular  phenotype/physiological
system from the pathogenic process in HdhQ111 mice as the
screen may not have captured an appropriate time-window for
its  detection.  These  factors  notwithstanding,  our  phenotypic
screen  revealed  a  number  of  interesting  phenotypes  in
heterozygous  HdhQ111  mice  (Table  1);  most  of  the  deficits
were  behavioral,  however  cardiovascular,  lung,  and  plasma
metabolite abnormalities were also found. These findings affirm
a growing body of data that the HTT CAG mutation results in
Figure 8.  Altered cardiovascular and lung parameters in HdhQ111/+ mice.  A. Pulse was measured in 12 week mice (N=10 per
group). A significant genotype p value (p<0.05) was obtained in a 2-way ANOVA. B. Tidal volume was measured in an independent
cohort of 18 week mice (n=6 per group). Tidal volume and other lung function measures were analyzed independently in males and
females by 2-tailed unpaired student’s t-test. * p<0.05. Plotted are Tukey box-whisker graphs.
doi: 10.1371/journal.pone.0080923.g008
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regions  may  be  particularly  susceptible  to  this  altered  state,
deficits  are  also  manifest  in  other  tissues.  Peripheral
phenotypes  are  of  considerable  interest  in  HD  as  these  can
provide  insight  into  disease  mechanism  in  readily  accessible
tissues and have the potential to lead to biomarkers of disease
onset/progression.
Behavioral abnormalities in HdhQ111/+ mice
While  behavioral  phenotypes  have  been  examined  in  a
number of knock-in HD mouse models to date [19-25,47-58]
many  of  these  previous  studies  have  concentrated  on
phenotypes exhibited by homozygous mutant mice. Focusing
on the phenotypes previously identified in heterozygous knock-
in mice as the most relevant comparison to those in the present
study,  there  appears  to  be  good  overall  agreement  between
the  models.  In  summary,  heterozygous  HdhQ175  mice
(C57BL/6J) exhibited decreased rearing, apparent at 16 and 32
weeks  of  age,  hypoactivity  from  20  weeks  of  age,  a  rotarod
deficit,  apparent  at  30  and  38  weeks  of  age  and  general
neurological  abnormalities  by  93  weeks  of  age  [57].
Heterozygous  HdhQ140  mice  (C57BL/6),  from  which  the
HdhQ175 mice were derived, showed decreased rearing at 12
weeks of age and a rotarod deficit at 48 weeks of age [55].
Heterozygous  HdhQ200  mice  (C57BL/6)  exhibited  a  motor
defect  on  the  balance  beam  at  50  weeks  of  age,  gait
abnormalities at 60-80 weeks of age, altered grip strength at 80
weeks of age, by which time the mice were moribund [54]. A
similar  pattern  of  heterozygous  phenotypes  was  seen  in  the
HdhQ150 line from which HdhQ200 was derived, but at later
ages  [48,51].  Thus,  in  general,  hypoactivity  and  motor
coordination  deficits  appear  relatively  early,  with  gait
abnormalities  and  more  general  neurological  abnormalities
apparent  at  later  ages.  Our  observations  in  B6J.HdhQ111/+
mice  are  consistent  with  this  general  pattern.  They  also
highlight  learning/memory  deficits,  and  uncover  both  novel
behavioral  phenotypes  as  well  as  some  of  the  earliest
behavioral  abnormalities  identified  to  date  in  heterozygous
knock-in mice.
The  earliest  behavioral  abnormality  we  detected  was
increased  time  spent  in  the  center  of  the  open  field  arena,
suggestive  of  decreased  anxiety.  Consistent  with  this  was  a
trend  towards  decreased  anxiety  in  the  light/dark  box.  Both
decreased  [59,60]  and  increased  [19,52,61]  anxiety  have
previously been reported in various rodent HD models tested in
a  number  of  different  paradigms.  Our  data  indicate  that
decreased anxiety may be a very early response to a single
mutant HTT allele, which, as previously hypothesized [59], may
reflect  the  stimulation  of  repair  mechanisms  such  as  the
release  of  anxiolytic  neurotrophic  factors  or  a
hypercompensatory  response.  An  early  compensatory
response is also indicated by a slight increase in motor learning
on  the  rotarod  in  HdhQ111  mice,  reminiscent  of  a  transient
increase in motor performance or activity previously observed
in other HD rodent models [49,59].
A deficit in the social discrimination task in male HdhQ111
mice suggests that these mice have impaired social recognition
memory.  Memory  deficits,  including  recognition  memory
deficits occur early in HD [32,62-64] and HdhQ111/+ mice have
previously  been  shown  to  exhibit  defects  in  long-term
recognition  memory  and  spatial  memory  by  4  months  and  8
months  of  age  respectively  [56].  Note  that  we  do  not  have
evidence  supporting  a  deficit  in  novel  or  familiar  object
recognition  (data  not  shown),  indicating  that  the  recognition
deficit uncovered in this screen is likely linked to the acquisition
of  olfactory  memories.  Social  recognition  memory  in  mice
depends  on  two  neuronal  pathways  for  the  acquisition  and
processing  of  olfactory  cues:  in  one  pathway  sensory
information from the olfactory epithelium is relayed through the
main olfactory bulb (MOB) to higher brain areas that include
the cortex and hippocampus. In the second pathway sensory
information from the vomeronasal organ is relayed through the
accessory olfactory bulb (AOB) to the amygdala, bed nucleus
of stria terminalis and hypothalamus [65]. As HdhQ111 mice
also exhibited a deficit in their ability to distinguish two different
odors it is possible that impairment in the social discrimination
task reflects an olfaction deficit, rather than a memory deficit.
However,  given  that  both  males  and  females  exhibited  an
olfaction  deficit  with  the  phenotype  appearing  slightly  more
severe in females (Figure 6), this is perhaps unlikely to explain
the male-specific defect in social discrimination. Furthermore,
while sensory information from the odors to which the mice are
exposed  in  the  olfactory  test  are  processed  via  the  MOB
pathway,  short-term  memory,  as  assayed  in  the  social
discrimination task described here, has a greater contribution
from the AOB pathway [66]. This suggests that the inability to
distinguish a novel and familiar mouse is likely to be due to a
defect  in  recognition  memory  that  may  reflect  an  underlying
deficit in the AOB pathway in HdhQ111 mice.
HdhQ111  mice  also  exhibited  markedly  reduced  odor
discrimination  without  any  loss  of  odor  sensitivity.  Olfaction
deficits are well documented in HD as well as in several other
neurodegenerative diseases, and in HD occurs in premanifest
gene carriers 15-20 years prior to disease onset [33-38,67,68].
Interestingly,  in  some  studies,  HTT  gene-positive  individuals
manifested  either  a  specific  defect  or  a  more  pronounced
defect  in  odor  discrimination  relative  to  other  olfactory
measures  [35,36],  paralleling  our  findings  in  the  mice.  The
absence  of  an  alteration  in  smell  sensitivity,  together  with  a
deficit during the training period, indicate that impaired olfactory
learning, rather than impaired olfactory perception, might more
likely underlie the odor discrimination phenotype in HdhQ111
mice. Reduced olfactory memory in female mutants, together
with  a  more  pronounced  training  deficit  in  female  mutants
suggests  that  these  phenotypes  may  result  from  common
underlying deficit(s).
The human caudate plays a role in odor discrimination [69],
suggesting  that  pathogenesis  occurring  in  HD  caudate  may
contribute  to  this  olfactory  deficit.  Of  note,  HdhQ111  mice
exhibit a time-dependent accumulation of mutant huntingtin in
the nucleus in specific brain regions. The striatum is the first
region  in  which  this  is  observed,  closely  followed  by  the
olfactory  tubercle  and  piriform  cortex  [11]  that  receive  direct
input from the main olfactory bulb [65,70]. While the underlying
cause  and  significance  of  nuclear  huntingtin  per  se  remains
unclear, it reflects an ongoing pathogenic process [12] and its
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interest to understand.
Interestingly,  some  odor  discrimination  tasks  and  olfactory
learning  are  dependent  on  adult-born  olfactory  bulb
interneurons [71-73 ] that arise from a proliferative stem cell
population  in  the  subventricular  zone  of  the  lateral  ventricle
[74].  Therefore,  the  impaired  olfactory  discrimination  in
HdhQ111  mice  may  reflect  abnormal  olfactory  bulb
neurogenesis and/or a defect in the function of these adult-born
neurons. Altered neurogenesis has been found in several HD
mouse  models  including  HdhQ111  [36,61,75-80].  Odor
discrimination  may  also  be  impaired  by  perturbations  to
olfactory  sensory  neurons  [81].  Further  experiments  will  be
needed to understand the cellular and molecular underpinnings
of the olfactory discrimination phenotype in HdhQ111 mice.
Peripheral abnormalities in HdhQ111/+ mice
We  identified  a  subtle  but  consistent  decrease  in  free-fed
blood  glucose  in  female  HdhQ111/+  mice.  Our  results
demonstrate  that  in  mice  up  to  19  weeks  of  age,  a  single
mutant  HTT  allele  does  not  induce  diabetes  or  impaired
glucose tolerance as seen in some patients as well as in N-
terminal  HTT  fragment  transgenic  mice  [42-44,82,83].
However, diabetes/glucose intolerance has not been seen in all
HD  patient  cohorts  examined,  and  it  has  been  argued  that
these  phenotypes  may  be  more  likely  associated  with  more
severe disease [84]. Our results indicate that rather than being
glucose  intolerant,  young  HdhQ111/+  mice  exhibit  signs  of
mildly increased glucose tolerance.
Blood glucose levels are controlled by the opposing actions
of insulin that stimulates glucose uptake, glycolysis, glycogen
synthesis and inhibits gluconeogenesis and counterregulatory
hormones,  principally  glucagon,  adrenaline,  growth  hormone
and  glucocorticoids  that  promote  gluconeogenesis  and
glycogenolysis, mainly in the liver. Interestingly, a similar, albeit
more severe phenotype of reduced blood glucose in a fed but
not in a fasting state was seen in mice carrying a liver-specific
deletion  of  the  gene  encoding  the  stimulatory  G  protein  α
subunit, thereby inhibiting glucagon signaling in the liver [85].
These mice exhibited increased glucose tolerance and insulin
sensitivity in the fed state, but were able to maintain normal
glucose levels in the fasting state despite impaired glucagon
signaling,  likely  due  to  excess  glycogen  stores,  increased
signaling by other counterregulatory hormones or sympathetic
nervous system activity. These mice also exhibited a reduced
fat content of which a trend was observed in HdhQ111/+ mice.
Therefore, we speculate that in HdhQ111/+ mice a mild defect
in gluoconegenesis induces a state of glucose tolerance in the
fed  state  that  can  be  compensated  under  fasting  conditions
where  counterregulatory  mechanisms  dominate.  Of  interest,
decreased gluconeogenesis has been proposed to account for
the  inability  of  HD  patients  to  increase  their  blood  glucose
levels following exercise [86].
While  the  effects  observed  in  young  HdhQ111/+  mice  are
small, weight loss apparent by 46 weeks of age supports the
occurrence  of  slowly-progressing  underlying  metabolic
disturbances. Of note, the weight loss in HdhQ111/+ mice was
more  prominent  in  females,  an  effect  also  observed  in  two
other lines of heterozygous knock-in mice (onset weight loss:
HdhQ175/+  females  15  weeks,  males  28  weeks  [57];
HdhQ200/+ 50 weeks, males maintained their weight up to 80
weeks [54]). It is unclear at this point whether this is related to
the  greater  tendency  towards  decreased  glucose  in  female
than  male  HdhQ111/+  mice  (Figure  7).  Taken  together,
however, our data hint that liver metabolism may be altered in
HdhQ111/+ mice. That the HTT CAG mutation impacts the liver
is indicated by late stage liver pathology in HD patients [87],
the presence of nuclear inclusions in hepatocytes in HD mouse
models [88,89] altered liver circadian function in vivo [90], and
more recently, direct evidence for reduced liver function in both
presymptomatic and symptomatic HD patients [91]. It is also
worth noting that the liver, together with the striatum, exhibits
the highest levels of somatic HTT CAG expansion in HdhQ111
mice,  predicted  to  accelerate  CAG  length-dependent
phenotypes  in  this  tissue  [27].  Our  results,  together  with
previous  observations  indicating  altered  metabolism  in  HD
knock-in mice [6,92-95], indicate that further investigation of the
metabolic state of both the liver and other tissues would be of
great interest.
We  observed  a  small  effect  of  the  HdhQ111  mutation  on
bone mineral density, with a decrease in mutant females and
an increase in mutant males. Decreased bone mineral density
has been observed in premanifest HTT mutation carriers [96]
and in the R6/2 HD transgenic mouse model [97] as well as in
other neurodegenerative diseases [98]. With the exception of
testosterone, the levels of which were unchanged in the mice in
this study (data not shown), factors that influence bone mineral
density,  such  as  glucocortocoids,  leptin,  vitamin  D  were  not
measured  in  this  screen.  Further  studies  will  be  needed  to
understand  the  mechanisms  underlying  the  putative  bone
remodeling in HdhQ111 mice, including the possible role of the
CNS [99].
Cardiovascular  and  lung  phenotypes  suggest  altered  ANS
function,  being  most  consistent  with  increased  sympathetic
activity at young ages. There is considerable evidence for ANS
dysfunction  in  both  manifest  and  premanifest  HD  individuals
[41,100-105]. In HD individuals cardiovascular autonomic tests
including  blood  pressure  response  to  sustained  hand-grip,
orthostatic  blood  pressure  test,  heart  rate  and  heart  rate
variability at rest and in response to maneuvers or stressors
revealed deficits in both the sympathetic and parasympathetic
branches of the ANS [41,100-105]. Our results support findings
of  altered  cardiovascular  parameters  in  other  HD  mouse
models  [106-108];  notably  an  increased  heart  rate  was
exhibited by both R6/1 and BACHD models [107,108]. Cardiac
phenotypes are of interest as early-onset cardiac disease is the
second leading cause of death in HD patients [109,110]. To our
knowledge, there has been no previous report of altered lung
function  in  HD.  ANS  deficits  in  HD  are  hypothesized  to
originate  in  the  central  autonomic  network,  consistent  with
cortical  and  hypothalamic  pathology  in  the  disease
[41,104,111-113]. It is worth noting that blood glucose levels
are  also  under  the  control  of  the  ANS;  thus  an  alternative
hypothesis  to  explain  the  slightly  depressed  glucose  levels
seen in HdhQ111 mice may be subtle alterations in centrally-
mediated  glucose  sensing  [114].  Our  results  prompt  further
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in HdhQ111 mice.
Conclusions
We have identified a number of phenotypes between 10 and
~50  weeks  of  age  in  HdhQ111  mice,  an  accurate  genetic
model of HD. Significantly, phenotypes were elicited by a single
full-length mutant HTT allele, as occurs in the majority of HD
patients. It is of interest that many of the phenotypes observed
were either sex-specific or more pronounced in one sex than
another. Sexually dimorphic effects of mutant huntingtin have
been  previously  observed  in  mice  [61,115,116],  and
understanding the basis for this would likely provide insight into
disease  pathways.  An  ongoing  goal  of  studies  in  HdhQ111
mice  is  to  identify  reproducible  early  disease-relevant
phenotypes  for  testing  of  genetic  and  pharmacological
modifiers. Early phenotypes in accurate genetic knock-in mice
are  predicted  to  be  subtle,  as  indicated  by  many  of  the
phenotypes  in  the  present  study.  While  subtle  phenotypes
would  not  necessarily  preclude  their  use  as  endpoints  in
modifier testing, further testing across multiple cohorts and at
multiple ages to identify the most robust phenotypes would be
of  value.  Importantly,  assessment  of  these  and  other
phenotypes in Hdh CAG allelic series in which mice differ in
CAG  repeat  length  will  be  important  in  prioritizing  those
phenotypes  that  are  most  relevant  to  the  CAG  length-
dependent pathogenic process in patients. Future studies will
also be aimed at a deeper understanding of the phenotypes
uncovered  in  this  screen  at  the  cellular  and  molecular  level,
with the aim of revealing potential novel therapeutic targets. .
Supporting Information
Figure  S1.    Acoustic  startle  response  and  prepulse
inhibition in HdhQ111/+ and wild-type mice. Acoustic startle
response  (ASR)  (top  graph)  and  prepulse  inhibition  (PPI)
(bottom graph) were measured at 13 weeks of age. ASR was
measured  at  background  noise  (NS)  and  sound  pressure
intensities of 70-120 dB. Note that there were small decreases
in  ASR  response  in  male  and  female  HdhQ111/+  mice,  but
these did not reach statistical significance. Sensorimotor gating
was  measured  by  PPI  at  a  startle  intensity  of  110  dB  and
prepulse intensities of 67, 69, 73 and 81 dB. “Global” is the
mean PPI value of all 4 prepulse intensities. N=20 HdhQ111/+
mice (10 males, 10 females) and N=21 Hdh+/+ mice (11 males,
10 females). Data points and bars represent mean±SEM.
(TIF)
Figure S2.  An olfactory deficit in HdhQ111/+ mice in an
additional cohort of males. Mice were trained on a scent [S+]
(either strawberry or apple) and then tested for their ability to
recognize  decreasing  proportions  of  this  scent  in  a  binary
mixture. Test carried out at MGH on males at 24-27 weeks of
age. N=10 per genotype.) Error bars show SEM. * p<0.05; **
p<0.01 in 2-tailed unpaired Student’s t-test comparing mutant
and wild-type mice at each dilution.
(TIF)
Figure  S3.    Test  of  olfactory  memory.  Mice  that  had
undergone  the  olfactory  discrimination  test  (GMC  pipeline  3)
were  re-tested  for  their  ability  to  recognize  the  odorant  on
which they had been initially trained [S+] after an interval of
either 16-17 weeks (A, C; mice trained to recognize strawberry)
or  20-22  weeks  (B,  D;  mice  trained  to  recognize  apple)
following the end of the initial testing period. The bar graphs
show  the  percentage  of  mice  that  correctly  recognized  [S+]
after an interval of either 16-17 weeks of 20-22 weeks. Each
graph represents data from 5 Hdh+/+ mice (white bars) and 5
HdhQ111/+  mice  (grey  bars).  Note  that  there  is  no  intrinsic
difference  between  the  apple  and  the  strawberry  odor  in
learning  acquisition  during  initial  training  (data  not  shown).
However,  it  is  unknown  whether  there  are  odor-specific
differences  that  relate  to  long-term  olfactory  memory,  and
therefore unclear whether apple-trained mice might also exhibit
a memory deficit at 16-17 weeks of age. Note that these data
are obtained from a single trial per mouse for 5 mice of each
sex  and  genotype.  Therefore,  although  all  5  tested  Hdh+/+
females  made  the  correct  choice  at  20  weeks,  while  all
HdhQ111/+ females made the incorrect choice, this should not
be interpreted as active avoidance of the “correct” odor in the
HdhQ111/+  mice,  but  rather  consistent  with  a  possible
difference in olfactory memory in the two genotypes that would
need to be followed up with further experiments with additional
mice and averaging several trials per mouse.
(TIF)
Figure  S4.    Intraperitoneal  glucose  tolerance  test.  An
intraperitoneal glucose tolerance test (IpGTT) was performed
at  14  weeks  of  age.  Following  fasting  for  16  to  18  hours
overnight  mice  were  injected  intraperitoneally  with  2  g  of
glucose/kg body weight using a 20% glucose solution. Blood
glucose was measured 15, 30, 60, 90 and 120 minutes after
glucose  injection.  N=10  per  group.  Plotted  are  mean  values
±SEM.
(TIF)
Table S1.  Tests performed in GMC pipelines of mice.
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Table S2.  Behavioral tests in MGH mouse cohorts.
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Table  S3.    Open  field  testing  in  the  dark  phase  in
HdhQ111/+ and Hdh+/+ mice at 56-59 weeks of age.
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Table  S4.    Body  weight  measurements  in  HdhQ111/+
versus wild-type mice.
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Table S5.  Clinical chemistry parameters in fed and fasted
HdhQ111/+ versus wild-type mice.
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